Insiders at
GE HealthCare Technologies made notable sales of shares while the stock experienced an alarming
14% crash. Despite the setback, various institutional shareholders, such as US Bancorp DE and Cambridge Investment Research Advisors Inc., increased their hold in GEHC stocks. Some experts express concerns about the risk attached to investing in GEHC currently, and Q1 2024 earnings missed expectations, which sparked the largest single-day loss since the company's spinoff. Despite these occurrences, analysts maintain a
'moderate buy' consensus rating on the stock. Partnerships have been struck with Nvidia, Biofourmis and Medis Medical to foster advancements. Weakness in the China market resulted in missed quarterly revenue estimates. However, GEHC remains a favourite amongst institutional investors with over a majority stake. Q1 2024 earnings analysis nears analyst expectations, with optimistic views on the company's growth prospects, as valuation is attractive. Concerns are raised about GEHC's returns on capital while, on the brighter side, the
release of new technology is boosting GEHC's stock.
Ge Healthcare Technologies GEHC News Analytics from Mon, 27 Nov 2023 08:00:00 GMT to Thu, 30 May 2024 12:01:06 GMT -
Rating -4
- Innovation 6
- Information 8
- Rumor -2
